SG11202008804UA - Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto - Google Patents
Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related theretoInfo
- Publication number
- SG11202008804UA SG11202008804UA SG11202008804UA SG11202008804UA SG11202008804UA SG 11202008804U A SG11202008804U A SG 11202008804UA SG 11202008804U A SG11202008804U A SG 11202008804UA SG 11202008804U A SG11202008804U A SG 11202008804UA SG 11202008804U A SG11202008804U A SG 11202008804UA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical compositions
- medium chain
- chain triglycerides
- methods related
- high drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643479P | 2018-03-15 | 2018-03-15 | |
| PCT/US2019/022478 WO2019178482A1 (en) | 2018-03-15 | 2019-03-15 | Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202008804UA true SG11202008804UA (en) | 2020-10-29 |
Family
ID=67908469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202008804UA SG11202008804UA (en) | 2018-03-15 | 2019-03-15 | Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210186915A1 (en) |
| EP (1) | EP3765002A4 (en) |
| JP (2) | JP2021518355A (en) |
| KR (1) | KR20200132950A (en) |
| CN (1) | CN112566629B (en) |
| AU (1) | AU2019236238A1 (en) |
| BR (1) | BR112020018765A2 (en) |
| CA (1) | CA3093703A1 (en) |
| EA (1) | EA202092092A1 (en) |
| IL (1) | IL277251A (en) |
| PH (1) | PH12020551470A1 (en) |
| SG (1) | SG11202008804UA (en) |
| WO (1) | WO2019178482A1 (en) |
| ZA (1) | ZA202005701B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018170235A1 (en) | 2017-03-15 | 2018-09-20 | Accera, Inc. | Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2775441B1 (en) * | 1998-02-27 | 2000-04-28 | Serobiologiques Lab Sa | MATRIX FOR THE PREPARATION OF MICROPARTICLES OR NANOPARTICLES, PROCESS FOR PRODUCING SUCH PARTICLES AND PARTICLES OBTAINED |
| TR200103188T2 (en) * | 1999-05-07 | 2002-04-22 | Pharmasol Gmbh | Lipid particles based on liquid and solid lipid mixtures. |
| US20080009467A1 (en) * | 2000-05-01 | 2008-01-10 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism |
| US20020006959A1 (en) * | 2000-05-01 | 2002-01-17 | Henderson Samuel T. | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism |
| JP6619744B2 (en) * | 2014-02-11 | 2019-12-11 | ファーネクストＰｈａｒｎｅｘｔ | Combination of baclofen, acamprosate, and medium chain triglycerides for the treatment of neurological disorders |
| SG11201700530PA (en) * | 2014-07-23 | 2017-02-27 | Food Science Inst Foundation | Agent for improving brain function and agent for preventing or treating cognitive impairment |
| US20190070124A1 (en) * | 2016-03-04 | 2019-03-07 | Sharon Anavi-Goffer | Compositions of cb2 receptor selective agonists for treatment of mental disorders |
-
2019
- 2019-03-15 EA EA202092092A patent/EA202092092A1/en unknown
- 2019-03-15 US US16/980,773 patent/US20210186915A1/en active Pending
- 2019-03-15 WO PCT/US2019/022478 patent/WO2019178482A1/en active Application Filing
- 2019-03-15 CA CA3093703A patent/CA3093703A1/en active Pending
- 2019-03-15 CN CN201980029076.8A patent/CN112566629B/en active Active
- 2019-03-15 AU AU2019236238A patent/AU2019236238A1/en active Pending
- 2019-03-15 KR KR1020207029620A patent/KR20200132950A/en unknown
- 2019-03-15 EP EP19766575.5A patent/EP3765002A4/en active Pending
- 2019-03-15 JP JP2020549612A patent/JP2021518355A/en active Pending
- 2019-03-15 SG SG11202008804UA patent/SG11202008804UA/en unknown
- 2019-03-15 BR BR112020018765-8A patent/BR112020018765A2/en unknown
-
2020
- 2020-09-09 IL IL277251A patent/IL277251A/en unknown
- 2020-09-14 PH PH12020551470A patent/PH12020551470A1/en unknown
- 2020-09-14 ZA ZA2020/05701A patent/ZA202005701B/en unknown
-
2023
- 2023-12-28 JP JP2023222223A patent/JP2024045146A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA202092092A1 (en) | 2021-02-15 |
| JP2021518355A (en) | 2021-08-02 |
| IL277251A (en) | 2020-10-29 |
| EP3765002A1 (en) | 2021-01-20 |
| CA3093703A1 (en) | 2019-09-19 |
| BR112020018765A2 (en) | 2020-12-29 |
| EP3765002A4 (en) | 2021-12-15 |
| KR20200132950A (en) | 2020-11-25 |
| JP2024045146A (en) | 2024-04-02 |
| WO2019178482A1 (en) | 2019-09-19 |
| PH12020551470A1 (en) | 2021-09-01 |
| US20210186915A1 (en) | 2021-06-24 |
| ZA202005701B (en) | 2022-07-27 |
| CN112566629A (en) | 2021-03-26 |
| CN112566629B (en) | 2023-11-17 |
| AU2019236238A1 (en) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3534919A4 (en) | Liver organoid compositions and methods of making and using same | |
| HRP20181534T1 (en) | Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | |
| IL255109A0 (en) | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| IL270714A (en) | Liver organoid compositions and methods of making and using same | |
| IL261444A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| ZA201906274B (en) | Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto | |
| EP3621593A4 (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases | |
| IL273125A (en) | Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof | |
| IL266132A (en) | Pharmaceutical formulations and methods of making the same | |
| EP3485887A4 (en) | Injectable pharmaceutical composition of tecovirimat and preparation method thereof | |
| EP3773654C0 (en) | Polypharmaceutical drug compositions and related methods | |
| ZA202005701B (en) | Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto | |
| EP3532052A4 (en) | Design and composition of cell-stabilized pharmaceutical formulations | |
| IL279877A (en) | Ivosidenib forms and pharmaceutical compositions | |
| EP3485886A4 (en) | Oral pharmaceutical composition of tecovirimat and preparation method therefor | |
| PL3176164T3 (en) | Optical isomer of 1,4-benzothiazepine-1-oxide derivative, and pharmaceutical composition prepared using same | |
| EP3612185A4 (en) | Pharmaceutical compositions comprising poh derivatives and methods of use | |
| ZA202104261B (en) | Combination pharmaceutical compositions and methods thereof | |
| GB201702603D0 (en) | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| EP3522890A4 (en) | Pharmaceutical resinate compositions and methods of making and using thereof | |
| IL308512A (en) | Stable liquid pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto | |
| EP4017488A4 (en) | Compositions and methods using non-steroidal anti-inflammatory drugs | |
| IL273904A (en) | Pharmaceutical resinate compositions and methods of making and using thereof | |
| GB201812022D0 (en) | Pharmaceutical methods and compositions | |
| AU2019903522A0 (en) | Pharmaceutical Compositions and Methods of Use |